LLM-based platform for generating new materials synthesis recipes dramatically cuts trial and error
A research team led by Professor Sung Beom Cho of Sungkyunkwan University (SKKU) in South Korea, in collaboration with Ajou University and MIT, has developed a closed-loop materials synthesis planning platform. This platform uses a large language model (LLM) to propose synthesis conditions for new materials and refines them based on experimental results. The team built a database from 4,407 open-access solid-state synthesis papers, applying a retrieval-augmented generation (RAG) method to suggest recipes. This approach successfully synthesized a single-phase new material for all-solid-state batteries within a few experiments, significantly reducing trial and error in materials design.
South Korean universities SKKU and Ajou, alongside MIT, have demonstrated a practical application of LLMs in materials science. Their platform, which leverages a database of 4,407 synthesis papers, uses AI to propose and refine recipes for new materials. This iterative process, where experimental feedback informs the LLM, cut down the trial and error for synthesizing an oxy-selenide-based solid electrolyte material for all-solid-state batteries. The initial AI-proposed 600°C condition led to impurities, but subsequent AI-guided adjustments to 450°C and 400°C quickly yielded a pure material. This shows how AI can accelerate R&D by integrating vast literature with real-world experimental outcomes. The immediate impact for Asia is in advanced manufacturing and battery technology, particularly for nations like South Korea and Japan that are heavily invested in these sectors. Reducing development timelines for new materials directly translates to faster innovation cycles and potential competitive advantages in critical industries. The methodology suggests a future where AI-assisted scientific discovery becomes standard, potentially lowering the barrier to entry for complex materials research and development across the region.
Share this article
Related reading
6 stories
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
Viva Biotech's interim results highlight AI's transformative role in drug R&D, mirroring this story's theme of AI accelerating scientific discovery.

Mastercard Expands APAC Dining Programme to 1,300 Restaurants

China’s Iluvatar CoreX’s first AI computing supernode squeezes most GPUs in 1 system

FIS Launches Agentic AI Tool for CFOs to Spot Cash Flow Risks Earlier

Mainland Chinese traders boost Hong Kong stock buying for fourth month as AI bets surge

